Member Info for TrickyEFC

Lets create a monster

Morning Andy yep hope the proper race starts soon 🐴

That would be faster than i envisaged.

Will it happen 💪

Was 5 to one on buying side.

Demand is here

First one is Nick's.

Will we get the shaking hand directors ping flash also..

What’s going on here?

Biotechnology company Solvonis Therapeutics has acquired Awakn Life Sciences, offering Awakn shareholders Solvonis shares and marking Awakn's delisting on May 28.

What does this mean?

This strategic acquisition, finalized from February 22, sees Solvonis Therapeutics taking over all outstanding common shares, RSUs, and DSUs of Awakn Life Sciences. Awakn's shareholders are set to receive 46.67 ordinary Solvonis shares per Awakn share, transforming the capital structure of both companies. The transaction also involves swapping all outstanding warrants, marking a major change in ownership. With Awakn's common shares scheduled for delisting from the Canadian Securities Exchange and OTCPink Market, this merger solidifies Solvonis’s progression in the biotech sector.

Why should I care?

For markets: Share reshuffle in the biotech scene.

The acquisition signifies a critical shift in biotech ownership dynamics, with the share restructuring likely to impact market activity. Investors should watch for changes in stock availability and pricing in Solvonis as Awakn exits public trading, potentially boosting Solvonis’s market position and attracting new investor interest.

The bigger picture: Biotech consolidation gains momentum.

This acquisition highlights a broader trend of consolidation in biotech, showing how companies are enhancing resources and market reach amidst competitive pressures. Such mergers could boost innovation, with firms like Solvonis set to utilize new capabilities from acquisitions to drive therapeutic advancements.

No one has been spiked here , i am invested as well .. please .. this is a massive re rate .. and traders will always sell chasing rainbows like yourself

Coming from tiger who has never posted on this board before today 😂😂😂😂😂

Is right Llama. Thought the news would be today.

So RNs tomorrow

Https://www.newsfilecorp.com/release/253532/Awakn-Life-Sciences-Announces-Completion-of-Arrangement-and-Sale-to-Solvonis-Therapeutics-plc

His disco one too.

And the rest

Fingers crossed

Given that the raise at 0.13p was 30% increase on the 1.8million last June would like to think that the new holders are of the investor mindset as opposed to flippers.

As llama has pointed out we ain't had any flippers as of yet and we now closer to the promised land and fully funded.

Llama ya like father Christmas on Xmas eve with your info.

Fentanyl and moving into other sectors I had not actually thought that far ahead.

So these guys mean serious business.👊

Llama as you say the board is solid as rock. The contacts and the networks available to Solvonis are vast, very vast.

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, specializing in commercialization, regional leadership and mergers and acquisitions. Mr. Carter is currently a Board Director and Committee Chair of four US listed BioPharma companies HutchMed PLC, Mallinckrodt Pharmaceuticals, Immatics NV, and VectivBio Inc.

Prior to this, Mr. Carter served as Executive Vice-President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company’s worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time. Before that Paul had senior leadership roles in GSK (and its legacy companies), including head of GSK China and head of Smith Kline Beecham Russia. He has lived and worked extensively in the US, Europe and Asia and continues to be strongly networked and professionally connected to a diverse range of publicly listed and private life science orientated businesses in these territories.

Stephen Page has worked at Chief Executive and Board level in UK healthcare for over 30 year, most noticeably leading Priory Healthcare, the largest network of mental healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organisations in both public and private sectors including Oxleas NHS Trust in London, Nestor plc and Acorn Care and Education.

As founding CEO of Acorn Care and Education, and supported by Phoenix Equity Partners, Steve built the company via acquisition and organic growth to be a leading national provider of special needs education and foster care. He led the sale to the Ontario Teachers’ Pension Plan in 2010.

Steve has a Business Studies Degree from Sheffield University and an MBA from London Business School

£1.60 a share. That would be close to 9 billion market cap?

Surely not off the £200 mill alone would we reach this value.

Llama this section of your post I applaud.

The way in which you have so perfectly encapsulated the clarity of the situation. Very excited for this week

It will happen, study the Awakn investors and now the svns investors.

Each year they have self funded this project, now moved it onto a more coveted London listing.

As soon as this gets passed, Big pharna comes sniffing

September 18, 2024

Awakn Announces Upsizing and Closing of Tranche of Private Placement Financing

TORONTO, CANADA, September 18, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (“AUD”), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the size of its previously announced non-brokered private placement financing (the “Offering”) from up to $1,000,000 to up to $2,000,000. Additionally, Awakn is pleased to announce the closing of a fourth tranche of the Offering through the issuance of an additional 857,143 units (the "Units") at a price of $0.46 per Unit for additional gross proceeds of $394,286 for a combined total of $1,117,142.

Llama your last post I was just thinking of some awakn news that supports that supports ya post.

Gonna see if can find it